Nektar Q4 Loss Wider Than Expected, Pipeline in Focus, Stock Up

Nektar Therapeutics (NKTR) incurred an adjusted loss per share of 15 cents in the fourth quarter of 2024, wider than the Zacks Consensus Estimate of a loss of 13 cents. In the year-ago quarter, the company had incurred a loss of 22 cents per share.See the Zacks Earnings Calendar to stay ahead of market-making news.Total revenues in the fourth quarter increased 22.2% year over year to $29.2 million. The reported figure however missed the Zacks Consensus Estimate of$39 million.In the past year, shares of Nek ...